cemacabtagene ansegedleucel

Cell therapy

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Company guidance: interim data expected mid-2027 (NCT06500273; Allogene Therapeutics, Inc., 6 Nov 2026). “We currently anticipate that a planned interim EFS analysis for ALPHA3 will occur in mid-2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Large B-Cell Lymphoma
NCT05714345 · Allogene Therapeutics
2023-11-01 – 2024-10-28 · Relapsed/Refractory Large B Cell Lymphoma
What this study did
Phase 1/2 (1)
Large B-Cell Lymphoma

Competitive landscape

This mechanism is crowded: 18 other tracked programmes target it, 3 of them ahead of this one.

This drug's own stage for Large B-Cell Lymphoma: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cemacabtagene Ansegedleucel: this drugPhase 2Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
Brentuximab VedotinApprovedAntibody–drug conjugateAnti-CD30 antibody-drug conjugatenot yet gradedNo reviewed efficacy summary in this indication
EpcoritamabApprovedMultispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
Inebilizumab
Approved(overall)
Monoclonal antibodyCD19
Reliable signal(overall)
No reviewed efficacy summary in this indication
Obecabtagene Autoleucel (Aucatzyl)
Approved(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
TafasitamabApprovedMonoclonal antibodyCD19Weak signal
NCT02399085: Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants
GolcadomidePhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Rondecabtagene AutoleucelPhase 3Cell therapyCD19 / CD20not yet gradedNo reviewed efficacy summary in this indication
SurovatamigPhase 3Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
Budoprutug
Phase 2(overall)
Monoclonal antibodyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
FT819
Phase 2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Rapcabtagene Autoleucel
Phase 2(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Beijing Biotech Anti-CD19 CAR-T
Phase 1/2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Zugocabtagene Geleucel
Phase 1/2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-319
Phase 1(overall)
Antibody–drug conjugateCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-519
Phase 1(overall)
—CD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
IC19 CAR-T
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
UTAA09
Phase 1(overall)
Cell therapyCD19
Weak signal(overall)
No reviewed efficacy summary in this indication
ZM001
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-619
—(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
FT522
—(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
GLPG5101
Discontinued
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Vispacabtagene Regedleucel
Discontinued
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow cemacabtagene ansegedleucel to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 2Large B-Cell LymphomaRecruiting
Est. primary completion 2027-12 · NCT06500273 · CT.gov ↗

Company guidance: interim data expected mid-2027 (Allogene Therapeutics, Inc., 6 Nov 2026). “We currently anticipate that a planned interim EFS analysis for ALPHA3 will occur in mid-2027.” Source ↗

What to watch
2029 (1)
February 2029 (1)
Phase 1/2Large B-Cell LymphomaActive not recruiting
Est. primary completion 2029-02 · NCT04416984 · CT.gov ↗
What to watch

See the full readout calendar ↗